Tempus AI to Acquire Personalis for $1.5B in Stock, Bringing MRD Test In-House
PSNL has more than doubled off its 52-week low of $3.84 on elevated volume (3.2× avg).
Summary
Tempus AI will acquire Personalis for $1.5 billion in stock, integrating its MRD test into Tempus' AI platform. The deal includes a floating exchange ratio and a cash election option, with closing expected by April 2027.
Key Events · M&A and Partnerships · PSNL
-
Acquisition by Tempus AI
Tempus AI will acquire Personalis for $1.5 billion in stock, combining Personalis' NeXT Personal MRD test with Tempus' AI-enabled precision medicine platform.
-
Merger Consideration Structure
Each Personalis share converts into Tempus stock at an exchange ratio of 0.3356 if Tempus' stock price is ≤ $48.42, or $16.25 divided by Tempus' stock price if above. Tempus may elect to pay cash for up to 50% of shares at $16.25 per share.
-
Termination Fees
Mutual termination fees of $76.8 million apply under certain circumstances, including if Personalis accepts a superior proposal or if regulatory conditions are not met due to Tempus' breach.
-
Voting Agreement with Merck
Merck, holding approximately 13% of Personalis' outstanding shares, has agreed to vote in favor of the merger, providing significant support for stockholder approval.
Analysis · PSNL · Industrial Applications And Services
In a move that reshapes the precision oncology landscape, Tempus AI will acquire Personalis in an all-stock deal valued at approximately $1.5 billion, integrating Personalis' NeXT Personal molecular residual disease (MRD) test directly into Tempus' AI-enabled platform. The merger agreement features a floating exchange ratio with a floor price of $48.42 for Tempus stock, a cash election option for up to 50% of Personalis shares at $16.25 per share, and mutual termination fees of $76.8 million. Merck, which holds 13% of Personalis, has agreed to vote in favor. Closing is expected by April 2027, subject to stockholder and regulatory approvals. While the combination of complementary technologies could accelerate adoption of MRD testing in oncology, the floating exchange ratio introduces risk for Personalis shareholders if Tempus' stock price declines.
At the time of this filing, PSNL was trading at $13.30 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $3.84 to $16.39. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.